IAdd image
Ipamorelin
PerformanceSingleA selective growth-hormone-releasing peptide often paired with CJC-1295.
Half-life
2 h
Common dose
70 – 210 mcg
Dosing frequency
Daily
Administration
Subcutaneous
How it works
Ipamorelin binds the ghrelin (GHS-R1a) receptor on pituitary somatotrophs, triggering pulsatile GH release. Unlike older GHRPs, it has minimal effect on cortisol, prolactin, or appetite.
Protocol notes
Most protocols dose 100–300 mcg subcutaneously 1–3 times daily — often before bed and post-workout. Cycles of 8–16 weeks. Almost always paired with a GHRH analog (CJC-1295 No DAC) for synergistic release.
Reported side effects
Generally well-tolerated. Possible head rush, mild hunger spike (less than GHRP-2/6), and injection-site reactions.
Additional research notes
GHRP. Often combined with CJC-1295. Typical dose 100–300mcg.